LTS Nasal & Sterile Drug Products (f/n/a Renaissance Lakewood, LLC), the New Jersey-based CDMO specialising in nasal drug delivery, is now in the midst of its next phase of growth following the completion of its acquisition by LTS.
The deal, completed on 7 November 2025, welcomes Renaissance Lakewood’s operations and workforce of around 500 employees into the LTS global network under a new division named “LTS Nasal & Sterile Drug Products.”
The acquisition brings Renaissance out of private-equity ownership and into a privately held organisation focused squarely on drug-delivery innovation.
Speaking to 24/7 Biopharma at CPHI, Eric Kaneps, Vice President at LTS- NAD, emphasised the strong fit between the two companies, noting that “we complement well, and we have no overlap in technologies.
“There are some common customers, but I really think there could be some excellent synergies for our clients as we introduce them to our additional capabilities,” he added.
Infrastructure Investment Delivered
The acquisition is the culmination of a multi-year expansion programme for Renaissance that began around 2020 and unfolded through several major milestones,
This included a $40m (€34.7m) investment in facilities and technology announced in 2021, the opening of a new flagship headquarters in New Jersey in May 2024, and the completion of its enlarged 67,000 sq ft warehouse and campus enhancement project in September 2024.
These upgrades have extended into packaging capabilities. This year, Renaissance installed two new secondary packaging lines – equipment ordered well before the recent tariff volatility and delivered in time to support rising commercial volumes.
“That new equipment allows us to do the complete packaging, serialisation, and directly ship to our clients, where in some cases our competition offer fill finish, and then send the devices off to a secondary co-packer,” Kaneps said. “That just creates complexity in supply chain and time, which we can help our partners avoid.”
Market Preferences Changing
CPHI and the expanse of Frankfurt’s Messe complex were an opportunity for Renaissance to reinforce its position as the “nasal experts.”
According to Kaneps, client interests were shifting: “I have seen a positive nasal trend right now, though it is a bit heavier in the multi-dose, both preserved and non-preserved,” he explained.
“Clients are looking for… more chronic use indications where you utilise 30, 40, 50 sprays, where one spray at a time becomes a bit too costly and cumbersome.”
This trend reflects a wider industry shift, with nasal delivery increasingly explored for chronic and neurological indications beyond traditional rescue-use products
Earlier this year, Kindeva Drug Delivery acquired Summit Biosciences, a specialist in intranasal drug development and manufacturing, to expand its capabilities in nasal drug–device combinations.
Meanwhile, Hovione has moved to broaden its footprint in the space through a collaboration with IDC to develop a next-generation nasal powder delivery device, reflecting growing demand for more advanced nasal formats beyond traditional liquid sprays.
Global Requirements Diverging
For many of Renaissance’s midsized US customers, the next growth phase lies overseas, with Europe and Asia priority destinations. But that expansion comes with regulators who don’t align, serialisation systems that rarely match, and testing regimes that shift from one market to the next.
“Right now we’re experiencing a lot of global growth… they all have different requirements, even sometimes different testing requirements. It sounds easy, like change the label, it’s much more complex than that.”
Global supply chains also remain under pressure. “Tariffs are interesting because a lot of our supply chain does come from Europe and China,” Kaneps noted.
“I’d rather [the tariff be set at] 10% rather than saying today it’s 10% then tomorrow it’s 15%. That makes it very difficult… every invoice is different.”
He added that GMP compliance and quality assurance remained the company’s “licence to operate,” noting Renaissance had “invested millions of dollars” to safeguard supply continuity.
Intranasal Pathways Emerging
As the company looks to the future, LTS is preparing to take a central role in the rapidly advancing arena of nose-to-brain delivery.
Here, Kaneps highlighted targeted nose-to-brain therapeutics as one of the most exciting new directions in drug delivery, driven by studies that show how intranasal formulations can migrate and settle within the brain.[1],[2]
“To me, that was kind of groundbreaking, where you can actually show where the drugs are hitting,” he said.
“In three to five years this will make it more realistic that we want to target this portion of the brain for this Alzheimer’s, Parkinson’s… These are big, big indications that don’t have great therapeutic solutions today.”
Even amid significant change, Kaneps is quick to underline stability: “We’re here to take care of our customers, our contracts, and the business that we’ve always been great at,” he said noting that additional capabilities will come with time.
With demand for nasal therapeutics surging and LTS’ global platform behind it, Renaissance is positioning not just to maintain its niche leadership but to play a more prominent role in shaping the future of nasal therapeutics.
[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC7076302/
[2] https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-025-00481-w
